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Decorin Antagonizes Angiogenesis
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A pertinent concept in the field of tumorigenesis is the
critical role of the extracellular matrix as an active
participant in the regulation of diverse cell processes
and signaling events that form an environment signified
by ever-changing flux (1). These diverse cellular
processes, permissive for tumor progression, are often
modulated by matrix constituents that culminate to
affect tumor invasion, metastasis and angiogenesis (2).
Various members of the proteoglycan gene family
are intimately involved in regulating tumor
angiogenesis by directly affecting key downstream
signaling pathways via interaction with ligands and
their cognate receptors (3-5). Decorin, a prototypical
member belonging to a superfamily of 18 individuallyencoded gene products collectively known as the small
leucine-rich proteoglycans (SLRPs)2 (6-8), has been
implicated in regulating angiogenesis.
Decorin was originally characterized to bind fibrillar
collagen, primarily type I, and to regulate fibrillogenesis
(9-16), tissue mechanical properties (17-21), and wound
healing and fibrosis (22,23). Decorin also regulates the
entry of Borrelia burgodferi spirochetes–the causative
agent of Lyme disease–into the dermis (24,25) and
several other pathophysiological processes including
dentin and bone mineralization (26-28), skeletal muscle
homeostasis (29), vertebrate convergent extension (30),
bone marrow stromal cell fate (31), myocardial
infarction (32), corneal transparency (33), various types
of nephropathies (34-38), and tumor inflammation (39).
In the context of cancer, decorin was first identified
as a proteoglycan highly induced in the stroma of colon
cancer (40,41) suggesting that decorin might counteract
the growth of malignant cells in a paracrine fashion.
Subsequently, it was discovered that decorin evokes
downregulation of multiple receptor tyrosine kinases
(RTKs) including the EGFR (42-45) as well as to other
ErbB family members (46). This signaling leads to
marked tumor growth inhibition (47), induction of the
cyclin-dependent kinase inhibitor p21WAF1/CIP1 (p21)
(48,49) and mobilization of intracellular Ca2+ stores in
cancer cells (50). Moreover, decorin has been found to

Capsule
Background: Decorin antagonizes multiple receptor
tyrosine kinases, such as Met, to suppress
tumorigenesis.
Results: Decorin promotes angiostasis by blocking
HIF-1α and β-catenin to inhibit VEGFA and MMP2/9
activity concurrent with thrombospondin-1 and TIMP3
induction.
Conclusion: Decorin abrogates the pro-angiogenic
HGF/Met signaling axis, thereby repressing VEGFAmediated angiogenesis under normoxia.
Significance: Soluble decorin attenuates early tumor
growth by preventing normoxic angiogenic signaling
through the Met receptor.
Decorin, a small leucine-rich proteoglycan, inhibits
tumor growth by antagonizing multiple receptor
tyrosine kinases including EGFR and Met. Here, we
investigated decorin during normoxic angiogenic
signaling. An angiogenic PCR array revealed a
profound decorin-evoked transcriptional inhibition
of pro-angiogenic genes, such as HIF1A. Decorin
evoked a reduction of HIF-1α and VEGFA in MDA231 breast carcinoma cells expressing constitutivelyactive HIF-1α. Suppression of Met with decorin or
siRNA evoked a similar reduction of VEGFA by
attenuating downstream β-catenin signaling. These
data establish a non-canonical role for β-catenin in
regulating VEGFA expression. We found that
exogenous
decorin
induced
expression
of
thrombospondin-1 and TIMP3, two powerful
angiostatic agents. In contrast, decorin suppressed
both the expression and enzymatic activity of MMP9
and MMP2, two pro-angiogenic proteases. Our data
establish a novel duality for decorin as a suppressor
of tumor angiogenesis under normoxia by
simultaneously
down-regulating
potent
proangiogenic factors and inducing endogenous antiangiogenic agents.
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via Met, which is antagonized by decorin. Further, our
findings indicate a novel induction of thrombospondin1 and TIMP3, coincident with the suppression of proangiogenic molecules. Thus, our data reinforce and
extend the critical role for decorin as an antagonist of
tumor angiogenesis.

antagonize the Met proto-oncogene (51) by receptor
internalization via caveolar-mediated endocytosis (52),
resulting in cessation of signaling analogous to EGFR
(53). This mode of action is in stark contrast to clathrinmediated endocytosis of Met (54) which enables Met to
maintain a prolonged activation of downstream
signaling (55).
Although decorin-null mice are apparently normal
(9), double mutant mice lacking decorin and p53
succumb very early to very aggressive lymphomas
suggesting that loss of decorin is permissive for
tumorigenesis (56). This concept is further corroborated
by a recent study using decorin-null mice in a different
genetic background. Under these conditions, lack of
decorin causes intestinal tumor formation, a process
exacerbated by exposing the mice to a high-fat diet
(57). Conversely, delivery of decorin gene or protein
retards the growth of a variety of cancers (58-65).
The role of decorin in tumor angiogenesis is
controversial. Previous reports have delineated a proangiogenic response, primarily on normal, nontumorigenic endothelial cells (66-68) or through loss of
decorin in the cornea (69). Interestingly, an antiangiogenic role for decorin has also been described in
various settings (70-72) and as an angiostatic agent
targeting tumor cells which exhibit dysregulated
angiogenesis via a reduction in vascular endothelial
growth factor (VEGF) production (73). The apparent
dichotomous effects reported for decorin on endothelial
cells and the perceived function on the tumor itself
creates a scenario where decorin is able to differentially
modulate angiogenesis. This is further substantiated by
a recent report where the expression of decorin was
evaluated as a function of tumor malignancy. Sarcomas
exhibited almost a complete absence of decorin in
contrast to hemangiomas, where decorin was
predominantly detected in the surrounding stroma (74).
Aside from the potent pro-migratory, pro-invasive, and
pro-survival roles inherent with aberrant Met activation
(75), the Met signaling axis is powerfully proangiogenic, specifically promoting VEGFA mediated
angiogenesis (76,77). These observations coupled to the
discovery of rapid and sustained physical
downregulation of Met evoked by nanomolar
concentrations of recombinant decorin (51,52) led us to
hypothesize that decorin could inhibit angiogenesis via
downregulation of the Met signaling axis.
In the present study, we provide mechanistic insight
supporting a functional link between decorin and the
Met signaling axis vis-á-vis the regulation of
pathological VEGF-mediated angiogenesis. The
angiostatic effects resulting in a marked inhibition of
VEGFA occur at both the transcriptional and posttranscriptional levels with upstream signaling occurring

EXPERIMENTAL PROCEDURES
Cells and Materials—HeLa squamous carcinoma and
MDA-MB-231 triple-negative breast carcinoma cells
were obtained from American Type Culture Collection
(Manassas, VA). MDA-MB-231 (hereafter referred to
as MDA-231 including derivative MDA-231 cell lines),
MDA-231(GFP+), wtHIF-1α and mutHIF-1α cells
were previously described (78). Cells were maintained
in Dulbecco’s Modified Eagle’s Medium supplemented
with 10% fetal bovine serum (FBS) (SAFC
Biosciences, Lenexa, KS) as well as with 100 μg/ml of
penicillin/streptomycin (MediaTech, Manassas, VA).
Human umbilical vein endothelial cells (HUVECs)
were purchased from Lifeline cells Technology
(Walkersville, MD) and used only within the first 5
passages. Primary antibodies against VEGFA (sc-152),
and Met (Met-C12, Sc-10) were from Santa Cruz
Biotechnology (Santa Cruz, CA); rabbit polyclonal antiβ-catenin (ab16051) and anti-MMP14 (ab3644)
antibodies were purchased from Abcam Inc. (Boston,
MA); mouse monoclonal anti-β-actin antibody was
from Sigma-Aldrich (St. Louis, MO). The anti-perlecan
antibody has been previously characterized (79,80).
Slot Blot Assay for the Analysis of Secreted VEGFA
— Cells were treated with decorin protein core in
DMEM for 24 h. Conditioned medium was collected,
filtered, then briefly centrifuged and applied to the slot
blot sample acceptor. Suction was applied for 30 min to
ensure attachment to the nitrocellulose membrane,
which was washed, and blocked overnight. Incubation
with a primary antibody specific for the secreted factor
was followed by application of an infrared-labeled
secondary antibody and subsequent visualization and
quantification via the Odyssey Infrared System.
Transient Knockdown of Met Receptor—Transient
knockdown of the Met receptor was achieved via
utilization of a cocktail consisting of three validated
siRNAs specific for Met mRNA (Met siRNA sc-29397
Santa Cruz). Briefly, six-well plates were seeded with
2x105 HeLa cells, followed by incubation overnight at
37°C until cultures were 70% confluent. Targeting
siRNA duplex at a final concentration of 80 pM was
added to diluted Lipofectamine 2000 (Invitrogen, Grand
Island, NY) in OPTI-MEM I Reduced Serum Medium
(GIBCO, Carlsbad, CA). Transfection was carried out
for 48 h at 37°C and the cells were then treated with
DMEM or decorin (500 nM) for an additional 24 h.
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Verification of siRNA-mediated knockdown of the Met
receptor was determined via immunoblotting using Met
specific antibodies.
Quantitative Real Time PCR Analysis—Gene
expression analysis by quantitative real-time
polymerase chain reaction (qPCR) was carried out as
described before (81) with minor modifications. Briefly,
sub-confluent (~1.5 x106 cells) 3.5 cm2 dishes of HeLa
cells were treated for 24 h with either PBS (mock) or
500 nM decorin protein core in DMEM. After
incubation, cells were lysed directly in 500 μl of TRIzol
Reagent (Invitrogen). Tumor RNA was obtained as
described before (52). Subsequent isolation of RNA
and cDNA synthesis proceeded as for cell culture. As
such, total RNA (1 μg) was annealed with Oligo (dT)
primers and cDNA was synthesized utilizing the
SuperScript Reverse Transcriptase II (Invitrogen)
according to the manufacturer’s instructions. Gene
specific primers were verified before use (supplemental
Table 1). The target genes and endogenous
housekeeping gene (ACTB) amplicons were amplified
in independent reactions using the Brilliant SYBR
Green Master Mix II (Agilent Technologies, Cedar
Creek, TX). All samples were run in quadruplicate on
an Mx3005P Real Time PCR platform (Agilent) or on a
LightCycle 480-II (Roche, Basel, Switzerland) and the
cycle number (Ct) was obtained for each independent
reaction. Fold change determinations were made
utilizing the Comparative Ct method for gene
expression analysis. Briefly, Delta Ct (ΔCt) values are
representative of the normalized gene expression levels
with respect to ACTB (β-actin as the endogenous
housekeeping control). Delta Delta Ct (ΔΔCt) values
represent the experimental cDNA (samples treated with
500 nM decorin protein core) minus the corresponding
gene levels of the calibrator sample (samples treated
with PBS mock). Finally, the reported fold change
represents an average of the fold changes as calculated
using the double ΔCt method (2-ΔΔCT). Data derive from
two-three independent trials for each gene of interest.
RT2 Profiler PCR Array—The specific expression of
angiogenic genes was evaluated using a human RT2
ProfilerTM PCR Array (SABiosciences) which
contained primers for the detection of 84-different
known angiogenic genes. This analysis was carried out
according to the manufacturer’s instructions. Briefly,
sub-confluent 3.5 cm2 dishes of HeLa cells were treated
for 24 h with either PBS (vehicle) or 500 nM decorin
protein core in DMEM. After incubation, the cells were
lysed directly in TRIzol Reagent (Invitrogen) for
subsequent RNA isolation. Total RNA was reverse
transcribed to cDNA using the RT2 First Stand Kit
(SABiosciences) followed by combination with the RT2
qPCR Mastermix. This volume was evenly distributed

among two PCR Array plates. Consecutive rounds of
qPCR were performed under normal thermal conditions
followed by data analysis according to the above
mentioned Comparative Ct method post normalization
to five independent controls.
Immunofluorescence—Immunofluorescent studies
was performed as described before (53,82,83).
Approximately 5 x 104 HeLa cells were plated on 4well chamber slides (BD Biosciences) and grown to full
confluence in 10% FBS at 37 ºC. Cells were switched to
DMEM/2% FBS 2 h prior to each treatment. Slides
were rinsed twice with DPBS and fixed/permeabilized
with ice-cold methanol for 10 min. Subsequently slides
were subjected to standard immunofluorescence
protocols, and mounted with Vectashield (Vector
Laboratories Inc, Burlingame, CA). Following
incubation with various primary antibodies, detection
was determined using goat anti-mouse IgG Alexa
Fluor© 488 and goat anti-rabbit IgG Alexa Fluor© 594
(Invitrogen). Images were acquired using a Leica
DM5500B microscope with Advanced Fluorescence 1.8
software (Leica Microsystems, Inc). All the images
were analyzed with Adobe Photoshop CS3 (Adobe
Systems, San Jose, CA). Fluorescence quantification
was done with ImageJ software.
Gelatinase Zymography—Gelatinase activities were
evaluated in tumor conditioned media (10 μl) collected
from HeLa cells after incubation with 500 nM decorin
for a period of 24 h were quantified with 10% SDSPAGE incorporating denatured rat tail type I collagen
(Sigma) (84). The sample buffer did not contain
reducing agents. Gels were washed in 2.5% v/v Triton
X-100 (1 h at room temperature) and incubated
overnight in 50 mM Tris HCl, pH 7.6, 0.1 mM NaCl, 10
mM CaCl2,, 0.05% Brij in the presence or absence of 20
mM EDTA (all from Sigma). Enzymatic activity was
visualized as negative staining with Coomassie Brilliant
Blue R-250 (Sigma) and quantified using Quantity One
1-D Analysis Software (Bio-Rad). The results of six
samples per group were averaged.
Quantification of MMP Levels—The detection of
total MMP-9 and MMP-2 present in tumor-conditioned
medium was carried out by ELISA according to the
individual kits assaying Human MMP-9 and Human
MMP-2
Immunossay
Quantikine
Colorimetric
Sandwich ELISA (R&D Systems, Minneapolis, MN)
according to the manufacturer’s protocol. These assays
employ a quantitative sandwich ELISA technique via a
monoclonal antibody specific for both the 92-kDa ProMMP9 (gelatinase B) as well as the 82-kDa-active
MMP9. Detection of human MMP-2 (gelatinase A) via
Human MMP-2 Quantikine kit was performed with a
polyclonal antibody cognant for the 72-kDa MMP2.
Briefly, tumor conditioned medium samples generated
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by a sub-confluent six-well plate of HeLa cells,
previously treated with either PBS (mock control) or
decorin protein core (500 nM) for 24 h, were collected.
The pre-coated plates received Assay Diluent followed
by application of standard, control, and sample cell
media aliquots followed by 2h incubation at 25 oC. The
plates were washed extensively, incubated with the
substrate for 30 min and read at 450 nm.
Evaluation of mRNA Stability—Determination of
mRNA decay processes were evaluated in HeLa via
pre-treatment of Actinomycin D (Sigma, St. Louis,
MO) for 1 h followed by treatment (4 h) with decorin
core protein (100, 500 nM). At the conclusion of the
experiment, media was aspirated, cells were washed in
PBS and lysed in TRIzol for RNA isolation and cDNA
synthesis (see above protocol). Yielded cDNA was
subsequently analyzed via qPCR (see above protocol
for workflow and ΔΔCt methodology) to evaluate the
resulting non-steady state mRNA levels of selected
target genes in the presence or absence of decorin.
MMP-9
Functional
Assay—Evaluation
of
endogenous MMP-9 activity present in HeLa
conditioned media in the absence or presence of decorin
core protein (500 nM) was carried out via utilization of
the SensoLyte® Plus 520 MMP-9 Assay Kit (AnaSpec,
San Jose, CA) (85,86). Briefly, following the 24 h
incubation with decorin, tumor conditioned DMEM was
collected, filtered (0.2 μm), and centrifuged. The
supernatant was subsequently used to generate two-fold
dilutions (up to and including 1:128). About 100 μl of
each dilution was added to each microplate well, which
contained a pre-coated monoclonal anti-human MMP9
antibody. Pulldown (1 h at 25 oC) of endogenous
MMP9 was succeeded by activation of the pro-MMP9
present only in the standard curve with 1 mM paminophenylmercuric acetate (APMA) for 2 h at 37 °C
but not for the control or experimental samples. This
allowed direct evaluation of endogenous active MMP9
in the applied samples. Next, active MMP9 activity was
assayed via the addition of the synthetic MMP9 5FAM/QXL520 FRET peptide. Following an 8-h
incubation with this MMP9 substrate, end point analysis
was determined by measuring the fluorescence
intensity, which measures the activity of MMP9, on a
BioTek Synergy 4 plate reader (BioTek Instruments,
Winooski, VT) at an Em/Ex of 490/520 nm.
Tumor Xenograft Matrigel Plug Assays—
Approximately 80 μl of MatrigelTM (BD Biosciences,
Bedford, MA) containing ~106 MDA-231(GFP+) cells
and HGF (10 ng/ml), in the presence or absence of
decorin (200 nM) were injected into 4 dorsal
subcutaneous regions of 6 severe combined
immunodeficient (SCID), nude, female mice (Charles
River Lab., Malvern, PA). Mice were sacrificed 14 days

post injection and their skins were removed, fixed in
10% buffered formalin (Fisher Science, Fair Lawn, NJ),
and then photographed from the inside to analyze the
resulting angiogenic reaction.
Quantification was
achieved by ImageJ software and superimposing grids
onto each photographed skin with each box of the grid
representing 1 mm2. Fifty, randomly-selected boxes
around each Matrigel plug were analyzed by
morphometry. That is, the number of times a blood
vessel intersected each box was recorded for both
“Matrigel+HGF” and “Matrigel+HGF+decorin”. Values
were converted into µm2 and a Student’s two-sided t
test (see below) was used to compare the values
obtained from the control and experimental conditions.
Tumor Xenografts—All animal studies were
approved by the Institutional Review Board of Thomas
Jefferson University. For orthotopic mammary tumor
xenografts, SCID female mice (Charles River Lab.,
Malvern, PA) were injected in the upper left mammary
glad with 1-2 x 106 MDA-231(GFP+) cells. The mice
were randomized once tumors were established. Half
the mice received a dose of 5 mg/kg decorin protein
core injected intraperitoneally every 2 days. The
controls received 100 μl PBS. On day 24, the majority
of animals were sacrificed and all major organs and
tumors were dissected and frozen subsequent to analysis
via immunofluorescence or qPCR. HeLa xenografts
were generated as described before (52).
Dot Blot Analyses of Secreted Factors—Evaluation
of secreted factors was done, in part, via dot blot
analysis. HeLa and MDA-231 cells were treated as
described under serum free conditions (see below).
Tumor cell conditioned medium was collected, filtered,
briefly centrifuged and applied to the dot blot (Minifold
I, Schleicher and Schuell, Keene NH) sample well plate.
Constant vacuum (~80 mbar) was applied for 30 min to
ensure attachment to the nitrocellulose membrane.
Membrane was washed, and blocked overnight in 5%
BSA. Incubation with primary antibody specific for the
secreted factor was followed by application of an HRPconjugated secondary antibody and subsequent
visualization with ECL technique. Densitometry was
performed with ImageJ software.
Quantification
and
Statistical
Analysis—
Immunoblots were quantified by scanning densitometry
using ImageJ software or using the Odyssey software
for the infrared-labeled secondary antibodies. All the
experiments were carried out in triplicate and repeated
at least three times. Results are expressed as mean
±SEM. Statistical analysis was performed with
SigmaStat for Windows version 3.10 (Systat Software,
Inc., Port Richmond, CA). Significance of differences
was determined by unpaired Student’s t test. Statistical
significance was achieved with p<0.05. For
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we normalized Ct values to endogenous ACTB in each
sample, we conducted qPCR to ensure the expression of
this housekeeping gene was not affected by exogenous
decorin. Thus, after 24 h we found that ACTB
(supplemental Fig. S1A) in HeLa was not significantly
modulated by decorin (500 nM). Further, we sought to
determine ACTB over time and demonstrate that up to 8
h in HeLa, ACTB mRNA levels also did not
significantly change (supplemental Fig. S1B).
Therefore, we conclude the changes seen in target gene
expression are not a result of β-actin modulation at the
mRNA level.
The expression changes were done at steady state
kinetics but could alternatively represent the effects of
decorin on modulating mRNA stability and/or
accelerating decay processes of the target message. To
address this possibility, we evaluated VEGFA, HIF1A,
and THBS1 in the presence of decorin following pretreatment with Actinomycin-D in HeLa. We found no
further changes in mRNA for VEGFA (supplemental
Fig. S1C), HIF1A (supplemental Fig. S1D) or THBS1
(supplemental Fig. S1E), indicating that decorin does
not modulate mRNA levels post-transcriptionally by
promoting mRNA decay. We can thus conclude that the
changes seen at the steady state reflect a decrease at the
level of transcription.
Collectively, these expression data implicate decorin
as a broad suppressor of the tumor angiogenic response
by exhibiting a unique duality. It effectively represses
pro-angiogenic gene targets under normoxia and
simultaneously promotes the expression of various antiangiogenic effector molecules.
Exogenous Decorin Potently Attenuates VEGFA
Signaling Components—Among the downregulated
genes reported in the expression analysis above, we
chose to focus on the VEGFA signaling axis as it relates
to tumor angiogenesis. First, we determined whether the
activity of decorin could be generalized to normal as
well as transformed cells. Thus, we tested two tumor
cell lines and normal endothelial cells for the effects of
exogenous decorin on VEGFA production. Following
decorin exposure, we found a uniform reduction of
secreted VEGFA in the media conditioned for 24 h by
HeLa (cervical carcinoma) and MDA-231 (triplenegative breast carcinoma) cells as well as from
HUVECs (p <0.001, Fig. 2 A,B).
The reduced levels of VEGFA found in the
conditioned medium could be a consequence of a
corresponding decrease in total cellular stores of
VEGFA or an inhibitory effect of VEGFA secretion. To
differentiate among these possibilities, we probed the
cell lysates using immunoblotting with the same antiVEGFA antibody. We found a decrease in cellular
VEGFA in both HeLa and MDA-231 and to a lesser

quantification
of
immunofluorescence
studies,
fluorescence intensity and 3D surface plots were
quantified by measuring pixels with ImageJ software as
described before (52).
RESULTS
Decorin Broadly Impedes the Transcription of ProAngiogenic Genes and Upregulates the Expression of
Angiostatic Genes—First, we determined the effects of
decorin on the expression of angiogenic genes using a
human RT2 ProfilerTM PCR Array (SABiosciences).
This PCR array platform profiles the expression of 84
key genes involved in modulating the biological
processes of angiogenesis, including growth factors and
their receptors, chemokines and cytokines, matrix and
adhesion molecules, proteases, as well as transcription
factors.
To this end, HeLa cells were treated for 24 h in the
absence or presence of 500 nM decorin protein core
under normoxic conditions whereupon total RNA was
harvested, reverse transcribed to cDNA libraries and
then applied to the cognate PCR Array plates.
Normalization of raw Ct values to five endogenous
controls allowed for a comparative ΔΔCt analytic
approach between calibrator samples (PBS control) and
experimental (decorin) samples. First, only ~10% of all
genes were changed: two were upregulated and six were
down-regulated by decorin (Fig. 1A). Notably, TIMP3
was induced over 4 folds by decorin and this product
has been previously shown to be antiangiogenic (87).
The six down-regulated genes, (Fig 1A) including
hypoxia inducible factor-1α (HIF1A), sphingosine 1phosphate receptor 1 (S1PR1), endoglin (ENG),
fibroblast growth factor 2 (FGF2), and integrin αV
(ITGAV), all were quite interesting because all have
been implicated in promoting key aspects of angiogenic
signaling (88-94), with the notable exception of
thrombospondin-1 (THBS1) which has been shown to
exhibit potent anti-angiogenic activities (95,96).
Next, we validated the modulated genes using qPCR
(Fig. 1B). The great majority of the transcriptional
changes reported by the PCR Array were reliably
reproduced. However, the expression changes for
aminopeptidase-N (ANPEP or CD13) and S1PR1 could
not be reproduced and validated most likely reflecting
either an exceedingly low transcript copy number or
sheer lack of expression in HeLa cells. Notably,
thrombospondin-1, a well-known anti-angiogenic factor
(95,96) was found to be slightly downregulated in the
presence of decorin (Fig. 1A). However, verification of
this gene via qPCR revealed THBS1 to be significantly
upregulated by ~ 2.5 folds (p<0.001, Fig. 1B).
Additional pro-angiogenic gene targets found to be
repressed by decorin included VEGFA and Met. Since
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established that VEGFA expression is transcriptionally
driven by HIF-1α (89,98).
Utilization of specific MDA-231(GFP+) cell lines,
which overexpress either wild-type HIF-1α (MDA-231
wtHIF-1α) or a mutated HIF-1α (MDA-231 mutHIF1α) allowed for direct evaluation of HIF-1α function in
normoxia. In the HIF-1α mutant, the proline residues
residing within the oxygen-dependent degradation
domain have been mutated to alanine (P402A and
P564A) that culminate in a constitutively-active HIF1α. This form is no longer a proper substrate for PHD2mediated hydroxylation and subsequent protein Von
Hippel-Lindau (pVHL)-dependent ubquitination leading
to proteasomal degradation. Thus, activated HIF-1α is
stable under normoxic conditions (78). We discovered
that decorin evoked downregulation of both wild-type
and mutant HIF-1α (Fig. 3A,B). Immunofluorescence
detection of both HIF-1α and VEGFA showed a
significant decrease in both wild-type and mutant cells
(Fig. 3C,D). We found that secreted VEGFA was also
reduced in the two cell types (Fig. 3E), further
supporting the data presented above. Thus, decorin
evokes downregulation of HIF-1α protein in mammary
carcinoma cells harboring either wild-type or a
constitutively-active HIF-1α.
Consistent with this notion, pVHL, the E3-ubquitin
ligase complex liable for degrading HIF-1α under
normoxic conditions (99) was upregulated nearly two
folds in MDA-231wtHIF-1α, but was unchanged in
MDA-231mutHIF-1α
(supplemental
Fig.
S3A)
following increasing concentrations of decorin. Further
evaluation of pVHL in parental MDA-231 cells
demonstrated a modest induction (supplemental Fig.
S3B); however, this was in contrast to the nearly 40%
inhibition of HIF-1α protein after 4 h (supplemental
Fig. S3B), which is consistent with the above findings.
Of note, treatment of HeLa demonstrated a similar trend
of modestly induced pVHL correlating with reduced
HIF-1α (not shown).
Collectively, these data posit a potential role of
pVHL, in conjunction with the already declining HIF1A
expression levels, for the early stages of HIF-1α
antagonism. Therefore, inhibition of HIF-1α does not
seem to rely as heavily on pVHL, instead decorin
evokes a prominent transcriptional repression. This
provides a novel role of attenuating traditional HIF1α/VEGFA signaling under normoxic conditions to
curb tumor growth.
Decorin Disables an Array of Activating
Transcription Factors Essential for the Proper
Expression of HIF1A and VEGFA Under Normoxia—
To further investigate the potential mechanism of
decorin antiangiogenic activity, we performed a detailed

extent in HUVECs (p<0.001 and p<0.01, respectively,
Fig. 2C, D). The difference in sensitivities among these
cell lines are attributable to higher Met in HeLa and
MDA-231 (6- and 8-folds higher, respectively) relative
to HUVEC (data not shown). Enhanced expression of
this high-affinity receptor would further sensitize the
cells to the angiostatic properties of decorin.
Next, we found a significant reduction of both
secreted and cellular VEGFA (supplemental Fig.
S2A,B) after 24h in HeLa and MDA-231 following
decorin treatment (100 nM). Thus, a concentration of
100 nM is sufficient to evoke reduction of secreted and
cellular VEGFA.
Time course experiments utilizing HeLa cell lysates
treated with a constant concentration of decorin
revealed a progressive decrease of both secreted (Fig.
2E,F) and cellular VEGFA (supplemental Fig. S2C)
relative to mock (PBS) treated controls for up to 12 h.
Downregulation of secreted and cellular VEGFA was
noted as early as 2 h (cfr. Fig. 2F and S2C); thus, we
conducted a VEGFA time course and found a gradual
reduction of VEGFA mRNA persisting for up to 8 h in
HeLa (supplemental Fig. S2D). Furthermore,
immunofluorescent analysis confirmed reduction of
cellular VEGFA in HeLa cells following decorin
treatment (supplemental Fig. S2E ).
Interestingly, cellular VEGFA levels maintained a
stable decrease starting at 8 h and lasting for up to 24 h,
which mirrored VEGFA expression. However, secreted
VEGFA seemed to have a sharper decrease at later time
points, potentially implicating an attenuation of the
secretory pathway.
Collectively, our findings indicate that decorin
affects VEGFA production in both transformed and
normal cells and further corroborate the marked
transcriptional inhibition obtained under normal oxygen
tension. Moreover, these data postulate a firm role for
decorin as a negative regulator of VEGFA by inhibiting
its expression at multiple levels of control.
Decorin Suppresses VEGFA in the Presence of
Constitutively-active
HIF-1α
under
Normoxic
Conditions—Further
interrogation
behind
the
mechanism of decorin-mediated suppression of VEGFA
signaling led us to evaluate the role of HIF-1α based on
the potent inhibition of HIF1A transcription under
normoxic conditions (cfr. Fig. 1). The HIF1A gene
encodes a key basic-helix-loop-helix transcription factor
that dimerizes with the constitutively expressed HIF1β/ARNT subunit to form a stable complex capable of
recruiting transcriptional co-activators such as
CBP/p300 to proximal promoters (97). Consequently,
the genetic subsets targeted by HIF-1α are primarily
responsible for orchestrating and executing the cellular
hypoxic response that will drive angiogenesis. It is well
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transfection of a cocktail of three validated siRNAs
targeting Met mRNA. We reasoned that Met
downregulation at the mRNA level would mimic the
proteasomal-induced degradation of Met evoked by
exogenous decorin.
The siRNA targeting Met reduced the receptor to
barely detectable levels without affecting β-actin levels
(Fig. 4A). Importantly, knockdown of Met recapitulated
the downregulation of cellular VEGFA (Fig. 4B).
Furthermore, dual treatment of HeLa cells with both
targeting siRNA followed by a 24 h incubation with
decorin did not result in additional inhibition of cellular
VEGFA, in agreement with Met acting as the main
signaling receptor for decorin-evoked inhibition of
VEGFA (Fig. 4B).
As discussed above, decorin suppresses the
transcription of targets critical for the promotion of
angiogenesis. Therefore, to dissect if decorin is
transducing these anti-angiogenic effects via Met, we
used siRNA targeting Met. This strategy achieved Met
transcript reduction by ~50% (Fig. 4C), relative to the
scrambled siRNA control. Interestingly, depletion of
Met alone induced transcriptional changes in VEGFA
and CTNNB1 analogous to decorin-treated HeLa cells
(Fig. 4C,E), but to a lesser degree. Finally, MYC a
downstream target of the Met/β-catenin antagonism
(52), was found to change only modestly (Fig. 4C).
Surprisingly, HIF1A expression was not appreciably
affected under these conditions (Fig. 4C). Several
reasons could account for this discrepancy such as the
requirement of decorin to evoke changes in HIF1A
expression vis-à-vis Met engagement, compensatory
mechanisms mediated via HIF-2α, or because signaling
is being integrated by decorin over multiple RTKs, such
as the EGFR.
As a primary downstream effector of Met (52), βcatenin was prominently reduced via decorin (Fig. 4 D).
This inhibition also extended to CTNNB1 transcripts
(Fig. 4E), to an extent comparable to MDA-231 wtHIF1α as shown previously (cfr. Fig. 3F). As decorin
downregulates Met protein levels via cavaeolarmediated endocytosis and proteasomal-dependent
degradation (47), we tested the effects of decorin on
MET transcript levels. Notably, we found a significant
reduction in the expression of MET (cfr. Fig. 1B)
indicating disruption of a positive feedback loop that
exists between Met and β-catenin upon decorin
engagement (102). It is tempting to speculate that
decorin is abrogating both β-catenin and Sp1 signaling
subsequent to Met degradation, resulting in
transcriptional inhibition of the VEGFA locus.
Importantly, this fosters a scenario wherein a growth
factor receptor dependent mechanism of HIF-1α
regulation is feasible, and is congruent with the

expression analysis of pertinent transcription factors
essential for driving the expression of both HIF1A and
VEGFA. Multiple transcription factors are known to
have consensus binding sites within the promoter of
VEGFA, in particular numerous sites are present for Sp1
and AP-1 as well as a HIF-1α response element (HRE)
(89). Coincidentally, these factors are also essential for
promoting and allowing HIF1A expression.
Taking this information into account we evaluated
FOS and SP1 expression within mutHIF-1α cells 4 h
and 24 h post exposure to decorin. The expression of
FOS was significantly decreased at both time points (p
<0.001 and p<0.01, Fig 3F,G), with a greater reduction
occurring after 4h with some recovery after 24 h. A
similar expression signature was obtained with SP1 at
both 4 and 24 h (p<0.001, 3F,G).
Next, CTNNB1 (β-catenin) expression exhibited a
reduction (p<0.001, Fig. 3F) following 4h; however,
after 24h, CTNNB1 expression seemed to recover
significantly (Fig. 3G), and return almost to baseline (p
<0.05, Fig. 3G). These data are congruent with the
finding of seven TCF/LEF binding sites embedded
within the proximal promoter of VEGFA (100) and thus
enforce the critical role of β-catenin signaling in the
promotion of VEGFA-mediated tumor angiogenesis.
Further, the expression of HIF1A decreased
significantly at 4h (p<0.01, 3F) and this was protracted
for up to 24 h (p<0.001, 3G). Finally, in regard to
VEGFA expression, both time points revealed a potent
suppression in MDA-231 mutHIF-1α cells (p<0.001,
Fig. 3F,G). Overall, these expression data corroborate
the above-mentioned protein and immunofluorescence
data.
In summary, these data argue for a role of decorin in
promoting a cessation of pro-angiogenic transcription
via a potent reduction in multiple genes necessary for
the expression of HIF1A and VEGFA. More importantly
is the ability of decorin to achieve potent angiostasis in
an activated HIF-1α cell line under normoxic
conditions. Further, classical Ras/MAPK signaling
cascades emanating from RTKs such as Met (see
below), are known to target and phosphorylate Sp1 via
the p42/p44 MAPK, resulting in full activation and
specific targeting of Sp1 to the proximal promoter of
VEGFA for competent transactivation (101).
The role of Met in Regulating Angiogenesis vis-à-vis
VEGFA Signaling—We have previously shown that
binding of decorin to Met is oppositional and
subsequent receptor internalization and degradation
ensues (52). Therefore, focusing on the prevalent
association of Met in the process of tumor angiogenesis
and the documented interaction with decorin, we
determined the link of Met in the process of decorinmediated angiostasis. This link was established via the
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gene expression analysis revealed an effective decrease
in MMP9 (p<0.001, Fig. 5D) and a modest but
statistically significant reduction in MMP2 (p<0.05,
Fig. 5D). We then performed ELISA with antibodies
specific for both MMPs and showed a significant
decrease in secreted MMP9 (p<0.001, Fig. 5E) without
any significant reduction in secreted MMP2 (Fig. 5F).
These data are uniformly consistent with the gelatin
zymography and gene expression data presented above.
Next, we evaluated the role of a membrane type
MMP, known as MT1-MMP (or MMP14) which proangiogenic and pro-invasive via the cleavage and
activation of MMP2 and MMP9 (108,109). To this end,
we carried out immunoblotting to detect MT1-MMP in
our HeLa samples and subsequently found no
significant change in MT1-MMP levels (Fig. 5G). We
also found no appreciable changes in the expression of
MMP14 (not shown).
Collectively, these data indicate that decorin is most
likely not attenuating MMP2/9 activity or expression
via modulation of a presumed upstream activator, i.e.
MT1-MMP. Moreover, these data provide further
evidence for the potent transcriptional control decorin
exerts over these loci by abrogating non-canonical βcatenin signaling.
Finally we evaluated the role of TIMP3, a secreted
protein that binds tightly to the extracellular matrix and
is also a direct inhibitor of ADAM-17/TACE (110).
TIMP3 has also been proposed to be a tumor suppressor
in several human cancers such as kidney, colon, brain,
memingomas, and non-small cell lung cancers (111113). Interestingly, TIMP3 has also been reported to
reduce Met receptor shedding (114). According to the
array (cfr. Fig. 1), decorin induces TIMP3 expression;
thus, we evaluated HeLa cell conditioned media and
found an almost 5-fold increase in secreted TIMP3
(supplemental Fig. S4A). Further, immunofluorescent
analysis of MDA-231(GFP+) tumor xenograft
cyrosections also revealed an abundant increase in
TIMP3 signal intensity (supplemental Fig. S4B), thus
indicating a decorin-dependent induction of TIMP3 in
vitro and in vivo.
We conclude that decorin suppresses the expression
and functional activity of MMP2/9 at least in part by
antagonizing Met signaling. This would result in a
protracted degradation and inhibition of β-catenin in a
non-canonical Wnt, RTK-dependent manner insofar as
both MMP2 and MMP9 are direct transcriptional targets
of β-catenin (107).
Decorin Induces Thrombospondin-1 both in Cell
Cultures and Tumor Xenografts—Next, we determined
the levels of secreted thrombospondin-1 in media
conditioned by HeLa cells that were exposed to either
vehicle (control) or decorin (500 nM) for 24 h. Using

biological activity decorin exerts on Met (103).
Notably, decorin-null mice have increased expression of
β-catenin in the enteric epithelium (57).
Further proof-of-principle of decorin mediated
angiostasis was established by employing a tumor
xenograft mouse Matrigel assay. To this end, we
injected ~106 MDA-231 (GFP+) cells mixed with ~80
μl of Matrigel and 10 ng/ml HGF in the absence or
presence of decorin (200 nM) into four dorsal
subcutaneous regions of SCID mice. After 14 days with
HGF, a strong angiogenic reaction was achieved
surrounding the tumors (asterisk, Fig. 4F, left panel).
This is in stark contrast to the combined treatment of
decorin and HGF for the same time period (asterisk,
Fig. 4F, right panel). Morphometric analysis of the
vessel density revealed a marked suppression of
vascularity associated with the decorin-containining
xenografts (p<0.001, Fig. 4G).
These in vivo findings argue a very strong case for
the ability of decorin to retard tumor angiogenesis in
MDA-231 tumor xenograft Matrigel assays. These data
establish and enforce a role of Met as being involved in
a non-canonical Wnt/β-catenin signaling pathway
induced by HGF to promote tumor angiogenesis vis-àvis VEGFA, which can be abrogated by decorin.
Decorin Inhibits the Induction and Activity of Matrix
Metalloproteinases—Aggressive neoplasms often show
increased expression of a class of zinc-dependent
gelatinases known as matrix metalloproteases (MMPs)
capable of degrading the matrix as well as liberating a
host of pro-angiogenic factors (104,105). Primarily
pertinent for the current study is the ability of matrixbound VEGFA to be released, making the factor readily
available for use by the surrounding angiogenic cells
(106). Taking this into account, we analyzed the
expression and activity of MMP9 and MMP2, both of
which are under the control of β-catenin signaling
(107). MMPs are secreted by the host cell as a zymogen
(otherwise known as the “proform”), followed by a
proteolytic cleavage event to yield the catalytically
active enzyme. Thus, to assess the activity of secreted
MMPs, media conditioned for 24 h by HeLa cells in the
absence or presence of exogenous decorin (500 nM)
were subjected to gelatin zymography. This functional
assay revealed a dramatic reduction in the activity of
MMP9 as well as a more modest, but still significant,
decrease in the activity of MMP2 (Fig. 5A) relative to
control conditioned media (p<0.001 and p<0.05,
respectively, Fig 5B). In agreement with gel
zymography, utilization of a MMP9 fluorescence
resonance energy transfer (FRET) probe assay revealed
>50% reduction in the activity of endogenous MMP9
present in HeLa conditioned media following decorin
treatment (Fig. 5C). In support of these functional data,
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oncogenes or the silencing of tumor suppressor genes
that drive a normal cell through transformation to a
malignant phenotype (115). A key milestone on the path
to cancer progression is the development of a competent
tumor vasculature to provide a blood supply as well as a
conduit for metastasis. This event is mediated via a
discrete step known as the angiogenic switch, which
results in an imbalance of key pro-angiogenic cytokines
and angiogenic inhibitors. Previous reports implicate
decorin as a powerful inhibitor of tumor angiogenesis
(73). In our current working model (Fig. 7) stromal
decorin engages and abrogates the HGF/Met signaling
axis, acting as a potent suppressor of VEGFA-mediated
tumor angiogenesis. Decorin binding to Met initiates
receptor internalization via increased phosphorylation
of Tyr1003, which is a recruitment site for the E3
ubquitin ligase c-Cbl. This mechanism triggers
caveolar-mediated endocytosis of the receptor complex,
culminating in the transcriptional repression of HIF-1α,
β-catenin, MYC, and SP1 under normoxic conditions,
coincident with decreased protein levels and
proteasomal degradation of HIF-1α, β-catenin, and
MYC (Fig. 7). The combinatorial effect of inhibiting
this constellation of transcription factors results in the
impairment of VEGFA, MMP2, and MMP9 expression,
and a simultaneous transcriptional induction of THBS1
and TIMP3, potent inhibitors of angiogenesis and the
MMP family. Moreover, we envisage that a concurrent
reduction of MMP2/9 activity coupled with induction of
thrombospondin-1 and TIMP3 allows for potent
angiostasis in the matrix, acting to further restrict
matrix-bound VEGFA from engaging cognate receptors
(e.g. VEGF-R2) on the surface of tumor endothelial
cells (Fig. 7). The potential involvement of MT1-MMP
(MMP14) was evaluated and found to be unchanged
since this membrane type MMP is postulated to
orchestrate several steps directly during cancer
progression including the degradation of physical
barriers (e.g. laminin-5) necessary for cancer cell
invasion (invadopodia), migration, activation of TGF-β,
and indirectly for tumor angiogenesis through cleavage
and activation of pro-angiogenic MMP2 and MMP9, at
the cell surface. MT1-MMP has also been reported to
remodel the basement membrane and regulate cell
proliferation during renal development (116).
Notably, thrombospondin-1 expression is negatively
regulated by Myc (117,118), thereby allowing
establishment of the angiogenic switch and tumor
progression, particularly of mammary epithelial cells
(119). Thus, an additional way through which decorin
could induce thrombospondin-1 would be via repression
of Myc (52). Moreover, HGF induces a severe
repression of THBS1 expression via activation of Met
(77). Thus, interference of the HGF/Met signaling axis,

quantitative dot blot analysis, we found a marked
increase in the secretion of thrombospondin-1 (Fig. 6A)
whereas the secretion of perlecan (internal control) was
not appreciably changed (Fig. 6B). Similarly, the
cellular levels of thrombospondin-1 were also
significantly increased by decorin (Fig. 6C).
Next, we utilized mice bearing HeLa tumor
xenografts which were treated with intraperitoneal
injections of decorin (5 mg/Kg) every other day over a
period of 23 days. At the end of the treatment, the
volume of the decorin-treated tumors was ~half the size
of vehicle-treated counterparts (p<0.001, n=6 per group,
Fig. 6D). Immunofluorescence analysis of frozen tumor
sections showed a marked induction of endogenous
human thrombospondin-1 in the treated tumor
xenografts (Fig. 6E). Concurrently, the amount of
endogenous VEGFA was markedly reduced in the
decorin-treated xenografts (supplemental Fig. S5).
Further in vivo relevance of decorin-mediated
angiostasis was determined via qPCR to evaluate the
expression of pro-angiogenic markers present in the
tumor xenografts. In the treated xenografts, there was a
substantial downregulation of MMP2, MMP9 and
VEGFA (p<0.001, Fig. 6F) and a marked upregulation
(up to 15 folds) of THBS1 (p<0.001, Fig. 6G)
transcription.
Overall, these data correlate well with the in vitro
findings and further strengthen the concept and current
rationale while providing a proof-of-principle for
decorin-mediated inhibition of VEGFA-mediated tumor
angiogenesis.
Systemic Administration of Decorin Inhibits Proangiogenic Markers in Orthotopic Tumor Xenografts —
To further strengthen the in vivo relevance of our data,
we generated orthotopic mammary tumor xenografts
using triple-negative breast carcinoma cells MDA231(GFP+). In this case, systemic treatment with
decorin protein core resulted in a marked induction of
endogenous human thrombospondin-1 by systemic
delivery of decorin (supplemental Fig. S6A). In
addition, the HeLa xenografts demonstrated an almost
complete loss of cellular VEGFA within the decorin
treated cohort relative to control animals when analyzed
via immunofluorescence and quantified as 3D surface
plots of the fluorescent signal (supplemental Fig. S6B).
Collectively, our results indicate that decorin can
simultaneously downregulate proangiogenic factors and
upregulate antiangiogenic factors in two animal models
of tumorigenesis.
DISCUSSION
The steps involved in tumor progression have been
derived from multiple animal models and reflect
discrete changes within the genome via activation of
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Our data presented here seemingly contradicts with a
previously published study (120) which reported that
decorin is able to induce VEGF production by
recruiting Sp1, HIF-1α, and STAT3 to the cognizant
response elements within the promoter of VEGF . This
study, however, was performed with murine cerebral
endothelial cells (120). Our study, in contrast, was
conducted in two human carcinoma cell lines. In this
context, the molecular repertoire and genomic profile of
malignant human cervical and breast cell lines
compared to normal mouse cerebral endothelial cells
make comparison difficult. Further, our data concerning
the effect of decorin for normal human endothelial cells
suggest an inhibitory role, which is supported by a
recent study demonstrating decorin antagonizes
VEGFR2 in human extravillous trophoblasts and
interfering with migration by attenuating ERK1/2
signaling (121).
In conclusion, our data demonstrate a novel
antagonistic interaction of the HGF-Met signaling axis
leading to a marked and sustainable inhibition of
VEGFA-mediated angiogenesis under normoxic
conditions. Potential therapeutic induction of this
mechanism of decorin, acting as a potent angiostatic
agent, will attenuate critical steps in the progression of a
malignant neoplasm and will have broad medicinal
applications as an angiostatic modality.

as coordinated by decorin, not only serves to repress
VEGFA but also acts to potently induce
thrombospondin-1, further preventing Met and VEGFA
mediated tumor angiogenesis.
We previously reported that stable expression of
decorin in several malignant cell lines led to inhibition
of endogenous VEGFA expression (73). However, the
mechanism of this effect was not investigated. In the
present study we have expanded these original
observations and unmasked a mechanism that is
controlled by a decorin-evoked downregulation of Met,
and perhaps other RTKs. An additional novelty of this
current study lies in the identification of a normoxic and
HIF-1α-dependent mechanism as a molecular basis for
these findings. Furthermore, at the time of publication
of our previous study, we were unaware of the recentlyestablished high affinity interaction of decorin with the
pro-angiogenic Met receptor (51). Abrogating the
EGFR activity by functionally blocking the receptor
with mAb425 or utilizing AG1478, in the presence of
decorin was able to evoke rapid activation of Met
followed by internalization and downregulation of total
Met levels, implicating Met as the primary receptor for
decorin. Finally, it was subsequently found that Met has
a substantially higher affinity for decorin relative to that
of EGFR (51).
This angiostatic effect has probable implications that
attenuate the initial stages of tumor angiogenesis. In this
phase, which precedes the activation of the angiogenic
switch, tumor hypoxia has not yet reached a
biologically relevant threshold to induce tumor
vascularization. This delineates a compelling role for
matrix-derived residents as being essential modulators
of early angiogenic events.
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The abbreviations used are: SLRPs, small leucine-rich proteoglycans; EGFR, epidermal growth factor receptor;
HGF, hepatocyte growth factor; RTK, receptor tyrosine kinase; VEGFA, vascular endothelial growth factor A;
HIF-1α, hypoxia inducible factor 1α; CDKI, cyclin dependent kinase inhibitor; p21, p21WAF1/CIP1; qPCR,
quantitative real-time polymerase chain reaction; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel
electrophoresis; MMP, matrix metalloprotease.
FIGURE LEGENDS

FIGURE 1. Decorin inhibits VEGFA-mediated angiogenesis by attenuating proangiogenic factors. A, RT2 PCR
Profiler Angiogenesis Array evaluating proangiogenic gene expression changes in HeLa cells following exposure to
500 nM decorin after 24 h. B, PCR array target gene verification performed via quantitative Real Time PCR
(qPCR) under the same conditions as in A. PCR Profiler Angiogenesis Array and all subsequent qPCR verification
analyses were performed in triplicate among three independent experiments, normalized to the endogenous
housekeeping gene, ACTB, and reported as average fold changes ±SEM in agreement with the Comparative ΔΔCt
Method (please see Experimental Procedures section for a full and detailed description).
FIGURE 2. Decorin potently attenuates VEGFA signaling. A, slot blot analysis of tumor conditioned medium in
the absence or presence of 500 nM decorin following a 24 h incubation to evaluate effects on secreted VEGFA in
cervical adenocarcinoma (HeLa), triple negative breast carcinoma (MDA-231), and normal human umbilical vein
endothelial cells (HUVEC). B, quantification of secreted VEGFA signal intensity for the above described cell lines,
normalized to total cell number. C, immunoblot analysis of HeLa, MDA-231, and HUVEC cell lysates treated in
the presence or absence of decorin (500 nM) for 24 h. Lysates were recovered and separated by 10% SDS-PAGE
and probed for cellular VEGFA. β-actin served as an internal loading control. D, immunoblot quantification
representing normalized fluorescence to β-actin for cellular VEGFA after decorin protein core treatment. E, slot
blot analysis of HeLa tumor cell conditioned medium treated with decorin protein core (500 nM) for the indicated
time points. F, quantification of secreted VEGFA time-course for the time intervals analyzed. Immunoassayed
proteins via slot blot and western blot were detected with IR-Dye conjugated secondary antibodies amenable for
visualization via the Odyssey Infrared Imaging System (LI-COR) with data representative of 2-3 independent
experiments run in duplicate and reported as mean ±SEM (**p < 0.01, ***p < 0.001)
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FIGURE 3. Decorin suppresses HIF-1α and VEGFA in constitutively-activated HIF-1α MDA-231 cells under
normoxic conditions and suppresses critical transcription factors needed for HIF1A and VEGFA expression.
A,B, immunoblot analysis of HIF-1α expression in either wild-type or mutant cell lines as indicated. Cells were
exposed for 4 h to increasing concentrations of decorin. The lower parts of the blots were stained with Coomassie
to demonstrate equal loading. The migration of molecular mass protein standards is shown on the left. C,D,
immunolocalization of HIF-1α and VEGFA in either wild-type or mutant cell lines as indicated. The cells were
treated for 4 h with decorin, fixed, permeabilized and reacted with antibodies specific for either HIF-1α or VEGFA.
Bar = 10 μm. E, quantification of secreted VEGFA obtained by slot blot analysis of media conditioned for 4 h by
either wild-type or mutant cells as designated. F, G, gene expression analysis of critical pathway genes found to be
essential for driving the expression of HIF1A and VEGFA after 4 h (F) or 24 h (G) of decorin as indicated. Data are
representative of at least two independent trials run in quadruplicate and were normalized to the endogenous house
keeping gene ACTB. Data are reported as percentage change ±SEM as calculated according to the Comparative
ΔΔCt Method (*p< 0.05, **p< 0.01, ***p< 0.001).
FIGURE 4. Decorin mediated attenuation of HGF/ Met signaling evokes potent angiostasis. A, immunoblot
verification of Met protein depletion following transient transfection of cognate targeting siRNA (80 pM)
(designated as siMet) in HeLa 48 h post transfection. B, immunoblot analysis following positive verification of Met
knock-down HeLa lysates probed for cellular VEGFA under conditions of control, decorin (24 h, 500 nM), siMet
(80 pM), or combined treatment and appear as a quantification of cellular VEGFA fluorescent intensity after
normalizing to β-actin. C, expression data gained from qPCR analysis of pertinent genes in the presence of siMet
(80 pM). Verification of siRNA functionality is delineated in this graph for Met. D, HeLa lysates were
immunoblotted for β-catenin and β-actin (as a loading control) under the influence of decorin (500 nM) for 24 h. E,
HeLa cDNA libraries evaluated for CTNNB1 via qPCR under the same experimental conditions as in D. F,
micrographs depicting high resolution digital images of mouse dorsal skin as it appears from the interior, 14 days
after subcutaneous injection with either Matrigel (80 ml combined with ~106 MDA-231 GFP+ cells) and HGF (10
ng/ml) in the absence (F, left panel) or presence (F, right panel) of decorin proteoglycan (200 nM). Asterisk
denotes Matrigel plug and tumor location. G, morphometric analysis of blood vessel density reported as vessel
intersections per μm2. Density was calculated by determining the average number of times the newly formed
angiogenic vessels intersected a grid, representing a standard area of 1mm2, which were superimposed onto the
images. The values represent the mean ±SEM (n= 600). Bar = 4 mm. Immunoblot and Met knockdown experiments
represent an average of at least 2 independent experiments performed in duplicate with quantification representing
the average ± SEM for cellular VEGFA. Gene expression data are a representative of 2-3 independent trials
reported as fold change ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001).
FIGURE 5. Decorin prevents the expression and activation of matrix metalloproteases necessary for tumor
extravasation, metastasis, and VEGFA liberation. A, HeLa cell conditioned medium treated with PBS or decorin
(500 nM) for 24 h was evaluated for enzymatic activity of MMP2 and MMP9 via gelatin zymography. B,
quantification of MMP9 and MMP2 enzymatic activity as determined in A as a function of relative MMP activity.
C, HeLa interrogated 24 h post decorin (500 nM) addition for the expression of MMP9 and MMP2 transcripts via
qPCR. D, ELISA of total MMP9 and MMP2 as indicated and found in HeLa cell conditioned medium (ng/ml/24h)
in the presence or absence of decorin (500 nM). Gene expression changes are reported as the average fold change ±
SEM collated over 2-3 trials performed in quadruplicate and normalized to the housekeeping gene ACTB. Gel
zymography and total MMP2/9 ELISA were repeated twice in triplicate (*p < 0.05, ***p < 0.001).
FIGURE 6. Decorin induces the anti-angiogenic factor, thrombospondin-1 both in cell cultures and in tumor
xenografts. A,B, media conditioned by HeLa exposed to either vehicle (control) or decorin (500 nM) for 24 h were
evaluated for the presence of secreted thrombospondin-1 and perlecan (as control). Notice that the levels of
thrombospondin-1 are significantly elevated by exogenous decorin (***p < 0.001, n=4). The values were obtained
by utilizing dot blots with serial dilutions of conditioned media (400-12.5 μl) and anti-thrombospondin-1 or antiperlecan antibodies and reported as the relative signal intensities of either secreted thrombospondin-1 or perlecan,
respectively. C, Western blot of cellular thrombospondin-1 from HeLa cells treated with or without decorin as
indicated. D, tumor volume of HeLa xenografts at day 23. Mice bearing HeLa xenografts were treated with
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intraperitoneal injections of decorin (5 mg/Kg) every other day over a period of 23 days (***p < 0.001, n=6 per
group). E, induction of thrombospondin-1 in the tumor xenografts by systemic delivery of decorin. The images
show representative frozen sections of HeLa xenografts at day 23 post-decorin treatment or control immunostained
for thrombospondin-1. All micrographs were imaged using the same exposure and gain. The right panels are 3D
surface plots of the corresponding images to the left which were generated with ImageJ software as described
before (47). Bar ~ 10 μm. F,G, qPCR analysis of mRNA extracted from HeLa xenografts at day 23 post-decorin or
control treatment. Data are from three independent trials run in quadruplicate and normalized to the endogenous
house-keeping gene ACTB. (***p< 0.001).
FIGURE 7. Schematic representation of proposed model for decorin-evoked angiostatic activity. Please refer to
the text for a detailed explanation.

16

